CSPC Pharmaceutical Group Ltd. logo

CSPC Pharmaceutical Group Ltd. (1093)

Market Closed
12 Dec, 08:00
7. 71
HKD
+0.02
+0.26%
HKD
58.91B Market Cap
11.41 P/E Ratio
0.64% Div Yield
84,766,364 Volume
0 Eps
7.69 HKD
Previous Close
Day Range
7.62 7.8
Year Range
4.27 11.63
Want to track 1093 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1093 closed Friday higher at 7.71 HKD, an increase of 0.26% from Thursday's close, completing a monthly decrease of -0.39% or 0.03 HKD. Over the past 12 months, 1093 stock gained 63.35%.
1093 pays dividends to its shareholders, with the most recent payment made on Nov 18, 2025. The next estimated payment will be in In 5 months on May 18, 2026 for a total of 0.14 HKD.
The last earnings report, released on Nov 20, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
CSPC Pharmaceutical Group Ltd. has completed 2 stock splits, with the recent split occurring on Oct 16, 2020.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

1093 Chart

Similar

Alibaba Health Information Technology Limited
5.27 HKD
+3.13%
Shanghai Henlius Biotech, Inc.
64.55 HKD
-0.23%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
438.6 HKD
+5.03%
Concord Healthcare Group Holdings Ltd.
1.8 HKD
-2.17%
Shanghai Microport Medbot Group Co., Ltd.
20.92 HKD
+1.06%

CSPC Pharmaceutical Group Ltd. (1093) FAQ

What is the stock price today?

The current price is 7.71 HKD.

On which exchange is it traded?

CSPC Pharmaceutical Group Ltd. is listed on XFRA.

What is its stock symbol?

The ticker symbol is 1093.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.64%.

What is its market cap?

As of today, the market cap is 58.91B.

Has CSPC Pharmaceutical Group Ltd. ever had a stock split?

CSPC Pharmaceutical Group Ltd. had 2 splits and the recent split was on Oct 16, 2020.

CSPC Pharmaceutical Group Ltd. Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. Cuilong Zhang CEO
HKEX Exchange
HK1093012172 ISIN
China Country
20,300 Employees
4 Jun 2025 Last Dividend
16 Oct 2020 Last Split
- IPO Date

Overview

CSPC Pharmaceutical Group Limited, positioned as an investment holding entity, delves into the realms of research, development, manufacturing, and sales of pharmaceutical products not only within the People's Republic of China but also across various regions globally including other parts of Asia, the Americas, and Europe. With its operations segmented into Finished Drugs, Bulk Products, and Functional Food and Others, CSPC stands out for its adeptness in addressing a wide array of medical conditions through its innovative pharmaceutical solutions. The strategic partnership with Pfizer Inc., particularly for the local launch of the COVID-19 oral treatment Nirmatrelvir/Ritonavir in China, underscores its commitment to contributing to global health crises responses. Formerly known as China Pharmaceutical Group Limited, its rebranding to CSPC Pharmaceutical Group Limited in March 2013 signifies a pivotal evolution in its journey since its establishment in 1992. The corporate headquarters nestle in Shijiazhuang, the People's Republic of China, marking its central hub for pioneering healthcare advancements.

Products and Services

  • NBP soft capsules and injections - Specifically designed for acute ischemic stroke treatment, providing critical care in times of severe cerebrovascular events.
  • Oulaining capsules and injections - Aimed at treating mild to moderate memory and mental impairment, ensuring cognitive health is maintained and improved.
  • Enxi - This medication is focused on the treatment of adult idiopathic Parkinson's disease, offering hope for those battling this debilitating condition.
  • Duomeisu - A powerful ally in the fight against lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors, showcasing CSPC's commitment to combating cancer.
  • Jinyouli - Designed to prevent leucopenia and infection induced by chemotherapy, safeguarding cancer patients from common treatment-related complications.
  • Keaili - Another key player in the battle against breast cancer, providing afflicted individuals with a beacon of hope.
  • Antibiotics, vitamin C, and caffeine APIs - Representing the bulk product offerings, these are essential components for a wide range of medical and consumer health products.
  • Functional food and glucose products - Moving beyond pharmaceuticals, CSPC offers products aimed at enhancing general health and well-being through dietary supplements and glucose management solutions.
  • Healthcare services - In addition to tangible products, CSPC extends its expertise into providing healthcare services, underscoring its holistic approach to health and wellness.

With a diversified portfolio addressing a broad spectrum of healthcare needs, from acute medical conditions to chronic illnesses, and a foray into functional foods, CSPC Pharmaceutical Group Limited exemplifies its role as a comprehensive healthcare provider. Through strategic partnerships and a relentless focus on innovation, CSPC continues to pave the way forward in the pharmaceutical industry, offering solutions that significantly improve patient care and treatment outcomes.

Contact Information

Address: No. 226 Huanghe Street
Phone: 86 31 1870 37015